Clinical trials: Psoriasis; Plaque
Psoriasis
An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)
The IMMagine study aims to validate the newly developed CLCI instrument (DermCLCI-p) in moderate to severe psoriasis (PsO) patients, who will be started on Risankizumb (RZB) treatment and will be enrolled into the validation…
- Trial name
- IMMagine (NCT05959070)
- Where
- 16 sites in Belgium, Canada and 1 more
- Volunteers
- 154 people
- Sponsor
- AbbVie
Plaque Psoriasis, Psoriasis (PsO)
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: How safe is taking ESK-001 long-term in people with moderate to…
- Conditions
- Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis
- Trial name
- ONWARD3 (NCT06846541)
- Testing
- Open-Label Envudeucitinib, Blinded Envudeucitinib
- Where
- 268 sites in United States, Australia and 14 more
- Volunteers
- 1,680 people
- Sponsor
- Alumis Inc
Plaque Psoriasis
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
The purpose of this research study is to evaluate the safety and tolerability of ILV-095 when it is given to individuals with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01010542
- Testing
- ILV-095 300 mg in a 4 to 1 ratio
- Where
- 9 sites in United States, Canada
- Volunteers
- 39 people
- Sponsor
- Pfizer
Psoriasis
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study which is designed to determine the efficacy, safety, immunogenicity and pharmacokinetics, and pharmacodynamics of HB0017 Injection in…
- Trial name
- NCT06477237
- Testing
- HB0017 Q4W, HB0017 Q8W
- Where
- 44 sites in China
- Volunteers
- 408 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Plaque Psoriasis Vulgaris
Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects
Plaque psoriasis vulgaris is a chronic inflammatory skin disorder, affecting 1-3% of the population in Europe and the United States of America (USA) and represents one of the most prevalent immune inflammatory diseases.
- Trial name
- NCT02976831
- Testing
- AZD0284
- Where
- United Kingdom
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Psoriasis
Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06
The purpose of this study is to evaluate the potential of DFD-06 to suppress the hypothalamic-pituitary-adrenal (HPA) axis when applied twice daily for 15 days.
- Trial name
- NCT03179605
- Testing
- DFD06
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Primus Pharmaceuticals
Psoriasis
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis
The clinical objective of this study was to determine the effect of BIRB 796 BS on pharmacodynamic markers of psoriasis as a measure of efficacy, to determine the population pharmacokinetics of BIRB 796 BS and to determine the…
- Trial name
- NCT02209753
- Testing
- BIRB 796 BS, low dose, BIRB 796 BS, medium dose 1, BIRB 796 BS, medium dose 2
- Volunteers
- 182 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-2 (NCT03611751)
- Testing
- BMS-986165, Apremilast
- Where
- 205 sites in United States, Australia and 14 more
- Volunteers
- 1,020 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis
This is a Phase I, randomized, placebo-controlled, single blind, parallel group, single-center study designed to evaluate immune responses during and after administration of 12 weekly SC doses of 1.0 mg/kg efalizumab in subjects…
- Trial name
- NCT00382512
- Testing
- Raptiva (efalizumab)
- Volunteers
- 60 people
- Sponsor
- Genentech, Inc.
Psoriasis
A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With Psoriasis
The purpose of this study is to further evaluate the safety of deucravacitinib treatment in Japanese patients with psoriasis in the real-world setting
- Trial name
- NCT06952465
- Testing
- Deucravacitinib, Any biologic treatment for psoriasis
- Where
- 2 sites in Japan
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Plaque Psoriasis
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with…
- Trial name
- MUSE (NCT04279119)
- Testing
- ARQ-151- cream 0.3%
- Where
- 12 sites in United States
- Volunteers
- 26 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Moderate to Severe Plaque Psoriasis
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05342428
- Testing
- TLL018 tablets
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Plaque Psoriasis
A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
- Trial name
- NCT06088199
- Testing
- Apremilast
- Where
- 30 sites in United States
- Volunteers
- 51 people
- Sponsor
- Amgen
Plaque Psoriasis
Study To Evaluate The Impact Of Difficult To Treat Sites On Biological Response In Moderate-To-Severe Plaque Psoriasis(PsO).
This study is to evaluate available local data in Iraq patients with moderate-to-severe plaque psoriasis on Enbrel treatment with regards to efficacy, treatment for PsO who have difficult to treat sites at presentation.
- Trial name
- NCT04428411
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 486 people
- Sponsor
- Pfizer
Plaque Psoriasis
Autologous Natural Killer Cells in Subjects With Plaque Psoriasis
This is a non-randomized, dose escalating and open-labeled clinical trial to evaluate the safety of autologous natural killer cell (NK) infusions (IV) of "SNK01" in adults with plaque psoriasis.
- Trial name
- NCT03894579
- Testing
- Study Product: SNK01
- Where
- Mexico
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- NKGen Biotech, Inc.
Psoriasis
A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )
This study is a Multicenter, Open-Label, Single-Arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of LZM012 Injection in Patients With Moderate to Severe Plaque Psoriasis.
- Trial name
- NCT07746479
- Testing
- LZM012
- Where
- China
- Volunteers
- 244 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Plaque Psoriasis
Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin.
- Trial name
- DREAM (NCT07039110)
- Where
- 84 sites in Canada, Czechia and 6 more
- Volunteers
- 700 people
- Sponsor
- AbbVie
Psoriasis, Plaque Psoriasis
Topical SGX302 for Mild-to-Moderate Psoriasis
To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.
- Conditions
- Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
- Trial name
- NCT05442190
- Testing
- Hypericin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Soligenix
Psoriasis
Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis
The study will investigate the efficacy and safety compared to placebo and the safety compared to ustekinumab of brodalumab in adolescents with moderate to severe plaque psoriasis.
- Trial name
- EMBRACE 1 (NCT04305327)
- Testing
- Brodalumab, Ustekinumab
- Where
- 35 sites in Belgium, France and 6 more
- Volunteers
- 12 people
- Sponsor
- LEO Pharma
Psoriasis
Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis
This Phase II study was designed as a multicenter, randomized, double-blind, placebo-controlled and 3-parallel arm, to assess clinical efficacy, safety, and tolerability of GN-037 versus clobetasol 17-propionate and placebo in…
- Trial name
- NCT05706870
- Testing
- GN-037, Clobetasol 17-propionate
- Where
- 18 sites in Turkey (Türkiye)
- Volunteers
- 190 people
- Sponsor
- GEN İlaç ve Sağlık Ürünleri A.Ş.